| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A synthesized peptide derived from human Histone H3 (symmetric di methyl R17) was used as the immunogen for the Histone H3 (symmetric di methyl R17) antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
Histone H3 (symmetric di methyl R17) Antibody / HIST1H3A is a anti-H3 Rabbit antibody Recombinant Rabbit Monoclonal clone 31H83 supplied in Liquid format. Recommended for workflows such as Western blot (WB), Immunocytochemistry (ICC), Immunofluorescence (IF) with listed reactivity in Human, Mouse.
Key elements and design rationale
- Target: H3
- Antibody details: Rabbit, Recombinant Rabbit Monoclonal, clone 31H83, isotype Rabbit IgG
- Format: Liquid
- Applications (as listed): WB, ICC, IF
Biological background
Histone H3 (symmetric di methyl R17) antibody is widely applied in epigenetics, developmental biology, and cancer research. Symmetric dimethylation at arginine 17 is generally associated with gene repression, acting through recruitment of repressive complexes and alteration of nucleosome interactions. By detecting this modification, researchers can investigate how arginine methylation shapes chromatin function.
ChIP with Histone H3 (symmetric di methyl R17) antibody identifies genomic regions enriched in this modification, revealing transcriptional silencing patterns. Western blotting distinguishes the modified form of histone H3, while immunofluorescence highlights nuclear localization and distribution within heterochromatin domains. These assays support detailed mapping of epigenetic landscapes.
Dysregulation of arginine methylation has been implicated in cancer, where altered PRMT5 activity promotes tumor growth and resistance to therapy. Histone H3 (symmetric di methyl R17) antibody therefore supports research into therapeutic targeting of arginine methyltransferases. The modification is also involved in stem cell regulation, X chromosome inactivation, and immune responses, broadening its biological significance.
Histone H3 (symmetric di methyl R17) antibody from
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- Immunofluorescence: visualize subcellular distribution and cell-to-cell heterogeneity.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Monoclonal antibodies provide a defined epitope recognition profile that can support consistent comparisons across experiments.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
